Adenomyosis: from scientific discoveries to the practical aspects of prescribing drug therapy


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Objective. To assess and analyze the results of 6-68-month treatment with dienogest 2 mg in patients with adenomyosis. Subjects and methods. Sixty-two reproductive-aged patients diagnosed with adenomyosis received therapy with dienogest 2 mg for 6 months, of whom 24.2% continued to take the drug for a longer period. Results. Diffuse adenomyosis was observed in most (87.1%) patients; focal or nodular adenomyosis was seen in 24.2% of patients. During a 6-month dienogest treatment cycle, 53.4% of patients showed a decrease in pain intensity, 31 % had complete pain relief; 70.7% of patients had significant uterine volume reduction. All the patients were noted to have a decrease in the intensity, frequency, and duration of bloody vaginal discharge. Conclusion. The authors’ own studies have established that the use of dienogest eliminates pain and abnormal uterine bleeding and decreases uterine volume in most patients. The therapy is characterized by good tolerance and can be used for a long time.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Marla Yarmolinskaya

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology; I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia

Email: m.yarmolinskaya@gmail.com

Maria Shalina

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: amarus@inbox.ru

Armine Khachaturyan

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology; Saint Petersburg State University

Email: armine2709@mail.ru

Elena Netreba

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: dr.netlenka@yandex.ru

Margarita Florova

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: fm.sergeevna@gmail.com

Svetlana Mekhtikhanova

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: svetlana-demb@mail.ru

Әдебиет тізімі

  1. Ярмолинская М.И., Айламазян Э.К. Генитальный эндометриоз. Различные грани проблемы. С.-Пб.: Эко-Вектор, 2017. 615 с.
  2. Garcia L., Isaacson K. Adenomyosis: review of the literature. Journal of minimally invasive gynecology. 2011; 18(4): 428-37. doi: 10.1016/j.jmig.2011.04.004
  3. Zhang Q., Duan J., Liu X., Guo S.W. Platelets drive smooth muscle metaplasia and fibrogenesis in endometriosis through epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation. Mol Cell Endocrinol. 2016; 428: 1-16. doi: 10.1016/j.mce.2016.03.015
  4. Cai X., Shen M., Liu X., Nie J. The Possible Role of Eukaryotic Translation Initiation Factor 3 Subunit e (eIF3e) in the Epithelial-Mesenchymal Transition in Adenomyosis. Reprod Sci. 2019; 26(3): 377-85. doi: 10.1177/19337191187734 9 0.
  5. Avtanski D., Garcia A., Caraballo B., Thangeswaran P., Marin S., Bianco J., et al. In vitro effects of resistin on epithelial to mesenchymal transition (EMT) in MCF-7 and MDA-MB-231 breast cancer cells - qRT-PCR and Westen blot analyses data. Data Brief. 2019; 25: 104118. doi: 10.1016/j.dib.2019.104118.
  6. Li Y., Zhang Q., Liu F., Zhang Z., Zou Y., Yang B., et al. Inhibition of formin like 2 promotes the transition of ectopic endometrial stromal cells to epithelial cells in adenomyosis through a MET-like process. Gene. 2019; 710: 186-92. doi: 10.1016/j.gene.2019.06.003.
  7. Qi S., Zhao X., Li M., Zhang X., Lu Z., Yang C., et al. Aberrant expression of Notch1/numb/snail signaling, an epithelial mesenchymal transition related pathway, in adenomyosis. Reprod Biol Endocrinol. 2015; 13: 96. doi: 10.1186/ s12958-015-0084-2.
  8. Luft F.C. Targeting epithelial-mesenchymal transition. J. Mol Med. 2015; 93(7): 703-5. doi: 10.1007/s00109-015-1302-2.
  9. Cho E.S., Kang H.E., Kim N.H., Yook J.I. Therapeutic implications of cancer epithelial-mesenchymal transition (EMT). Arch Pharm Res. 2019; 42(1): 14-24. doi: 10.1007/s12272-018-01108-7.
  10. Greening D.W., Gopal S.K., Mathias R.A., Liu L., Sheng J., Zhu H.J., et al. Emerging roles of exosomes during epithelial-mesenchymal transition and cancer progression. Semin Cell Dev Biol. 2015; 40: 60-71. doi: 10.1016/j. semcdb.2015.02.008
  11. Papageorgis P. TGFbeta Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis. J. Oncol. 2015; 2015: 587193. doi: 10.1155/2015/587193
  12. Khan K.N., Kitajima M., Hiraki K., Fujishita A., Nakashima M., Masuzaki H. Involvement of hepatocyte growth factor-induced epithelial-mesenchymal transition in human adenomyosis. Biol Reprod. 2015; 92(2): 35. doi: 10.1095/biolre-prod.114.124891.
  13. Ding D., Liu X., Duan J., Guo S.W. Platelets are an unindicted culprit in the development of endometriosis: clinical and experi- mental evidence. Hum Reprod. 2015; 30(4): 812-32. https://doi.org/10.1093/humrep/ dev025
  14. Liu X., Shen M., Qi Q., Zhang H., Guo S.W. Corroborating evidence for platelet-induced epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation in the development of adenomyosis. Hum Reprod. 2016; 31(4): 734-49. doi: 10.1093/humrep/dew018.
  15. Gonzalez D.M., Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2014; 7: 8. doi: 10.1126/scisignal.2005189.
  16. Parasuraman P., Mulligan P., Walker J.A., et al. Interaction of p190A RhoGAP with eIF3A and other translation preinitiation factors suggests a role in protein biosynthesis. J. Biol Chem. 2017; 292(7): 2679-89.
  17. Cai X., Shen M., Liu X., Guo S.W. Reduced Expression of Eukaryotic Translation Initiation Factor 3 Subunit e and Its Possible Involvement in the Epithelial-Mesenchymal Transition in Endometriosis. Reprod Sci. 2018; 25(1): 102-9. doi: 10.1177/1933719117702248.
  18. Huang T.S., Chen Y.J., Chou T.Y., Chen C.Y., Li H.Y., Huang B.S., Tsai H.W., et al. Oestrogen-induced angiogenesis promotes adenomyosis by activating the Slug-VEGF axis in endometrial epithelial cells. J. Cell Mol Med. 2014; 18(7): 1358-71. doi: 10.1111/jcmm.12300.
  19. Osada H. Uterine adenomyosis and adenomyoma: the surgical approach. Fertility and sterility. 2018; 109(3): 406-17. https://doi.org/10.1016/j. fertnstert.2018.01.032
  20. Рухляда Н.Н., Крылов К.Ю., Бирюкова Е.И. Органосохраняющие операции при аденомиозе. Акушерство и гинекология. 2019; 5: 86-9.
  21. Цхай В.Б., Микаиллы Г.Т., Костарева О.В., Каплунов В.А., Руф Р.Р. Беременность и роды после радикальной аденомиомэктомии и метропластики по методике Хисао Осада у женщин с диффузным аденомиозом, ассоциированным с бесплодием. Российский вестник акушера-гинеколога. 2019; 19(2): 63-7. https://doi. org/10.17116/rosakush20191902163
  22. Kishi Y., Yabuta M., Taniguchi F. Who will benefit from uterus-sparing surgery in adenomyosis-associated subfertility? Fertil steril. 2014; 102(3): 802-7. https:// doi.org/10.1016/j.fertnstert.2014.05.028
  23. Sizzi O., et al. Italian multicenter study on complications of laparoscopic myomectomy. J. minimal invas gynecol. 2007; 14(4): 453-62. https://doi. org/10.1016/j.jmig.2007.01.013
  24. Strowitzki T. Strowitzki, T., Marr, J., Gerlinger, C., Faustmann, T., Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Human Reproduction. 2010; 25(3): 633-41. https://doi.org/10.1093/humrep/dep469
  25. Miyashita M., Koga K., Takamura M., Izumi G., Nagai M. et al. Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecological Endocrinology. 2014; 30(9): 644-8. https://doi.org/10.3109/09513590.2014.911279
  26. Yamanaka K., Xu B., Suganuma I., Kusuki I., Mita S., Shimizu Y., et al. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic stromal cells in spheroid culture. Fertil steril. 2012; 97(2): 477-82. https://doi.org/10.1016/j.fertnstert.2011.11.005
  27. Ярмолинская М.И., Флорова М.С. Возможности терапии диеногестом 2 мг у больных наружным генитальным эндометриозом. Проблемы репродукции. 2017; 23(1): 70-9. doi:10.17116/ repro201723170-79.
  28. McKinnon B.D., Bertschi D., Bersinger N.A., Mueller M.D. Inflammation and nerve fiber interaction in endometriotic pain. Trends Endocrinol Metab. 2015; 26(1): 1-10. https://doi.org/10.1016/j.tem.2014.10.003
  29. Mita S., Shimizu Y., Sato A., Notsu T., Imada K., Kyo S. Dienogest inhibits nerve growth factor expression induced by tumor necrosis factor-α or interleukin-1 p. Fertil steril. 2014; 101(2): 595-601. https://doi.org/10.1016/ j.fertnstert.2013.10.038
  30. Osuga Y., Watanabe M., Hagino A. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis. J. Obst Gynaecol Research. 2017; 43(9): 1441-8. https://doi.org/10.1111/jog.13406
  31. Fawzy M., Mesbah Y. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial. Arch Gynecol Obstet. 2015; 292(6): 1267-71. https://doi.org/10.1007/s00404-015-3755-5
  32. Neriishi K., Hirata T., Fukuda S., Izumi G., Nakazawa A., Yamamoto. Longterm dienogest administration in patients with symptomatic adenomyosis. J. Obstet Gynaecol Research. 2018; 44(8): 1439-44. https://doi.org/10.1111/ jog.13674
  33. Prathoomthong S., Prathoomthong S., Tingthanatikul Y., Lertvikool S., Rodratn N., Waiyaput W., et al. The effects of dienogest on macrophage and natural killer cells in adenomyosis: a randomized controlled study. Int J. Fertil Steril. 2018; 11(4): 279-86. doi: 10.22074/ijfs.2018.5137.
  34. Vercellini P., Vigano P., Somigliana E., Daguati R., Abbiati A., Fedele. Adenomyosis: epidemiological factors. Best Pract Res Clin Obstet Gynaecol. 2006; 20(4): 465-77. https://doi.org/10.1016/j.bpobgyn.2006.01.017
  35. Bromley B., Shipp T. D., Benacerraf B. Adenomyosis: sonographic findings and diagnostic accuracy. J. Ultrasound Med. 2000; 19(8): 529-34. https://doi. org/10.7863/jum.2000.19.8.529
  36. Айламазян Э.К., Ярмолинская М.И., Молотков А.С., Цицкарава Д.З. Классификации эндометриоза. Журнал акушерства и женских болезней. 2017; 66(2): 77-92. doi: 10.17816/JOWD66277-92.
  37. Pistofidis G., Makrakis E., Koukoura O., Bardis N., Balinakos P., Anaf V. Distinct types of uterine adenomyosis based on laparoscopic and histopathologic criteria. Clin Experiment Obstet Gynecol. 2014; 41(2): 113-8.
  38. Kunz G., Beil D., Huppert P., Noe M., Kissler S., Leyendecker G. Adenomyosis in endometriosis-prevalence and impact on fertility. Evidence from magnetic resonance imaging. Human Reproduction. 2005; 20(8): 2309-16. https://doi. org/10.1093/humrep/dei021
  39. Vercellini P., Consonni D., Dridi D., Bracco B., Frattaruolo M. Uterine adeno-myosis and in vitro fertilization outcome: a systematic review and meta-analysis. Human Reproduction. 2014; 29(5): 964-77. https://doi.org/10.1093/humrep/ deu041
  40. Razavi M., Maleki-Hajiagha A., Sepidarkish M., Rouholamin S., Almasi-Hashiani A., Rezaeinejad M. Systematic review and meta-analysis of adverse pregnancy outcomes after uterine adenomyosis. Int J. Gynaecol Obstet. 2019; 145(2): 149-57. doi: 10.1002/ijgo.12799

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2020